Shenzhen Main Luck Pharmaceuticals, Inc.

Main objective: Using placebo as control, analyze the changes in 6-minute walk distance (6MWD) 16 weeks after the start of treatment compared with baseline, and evaluate the effectiveness of beraprost sodium sustained-release tablets in the treatment of IPAH, HPAH and CTD-PAH patients with WHO cardiac function grade Ⅰ-Ⅲ.

Primary objective: To evaluate the efficacy and safety of bexarotene capsules as a monotherapy in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have received at least one previous systemic therapy in the Chinese population with cutaneous T-cell lymphoma (CTCL). Secondary objective: To conduct a pharmacokinetic study of bexarotene capsules 300 mg/m2/d in the Chinese population with CTCL.

Main research purpose This study examines the single oral administration of mirabegron sustained-release tablets (test preparation, specification: 25 mg/tablet) developed by Shenzhen Wanle Pharmaceutical Co., Ltd. and mirabeg produced by Avara Pharmaceutical Technologies, Inc. under postprandial conditions. The pharmacokinetic characteristics of Longon sustained-release tablets (reference preparation, specification: 25mg/tablet, trade name: Betmiga®/Betanil®) were evaluated to evaluate the bioequivalence between the two preparations. Secondary research purpose To evaluate the safety of the test preparation and reference preparation (trade name: Betmiga®/Betanil®) of a single oral administration of 25 mg mirabegron extended-release tablets in healthy subjects.